DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

Information source: BeerYaakov Mental Health Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Placebo (Drug); Trazodone (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: BeerYaakov Mental Health Center

Summary

Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with akathisia according to DSM-IV criteria at least mild akathisia.

Exclusion Criteria:

- Change of pharmacologic regimen 7 days prior to study entry

- Significant systemic disease

- The presence of chronic akathisia

- Patients unable to cooperate

Locations and Contacts

Beer Yaakov MHC, Beer Yaacov 70350, Israel
Additional Information

Starting date: November 2000
Last updated: June 15, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017